In summary, these data are the first to demonstrate the efficacy of adenosine A2A receptor agonists against APS-accelerated venous thrombosis, with agonists functioning almost identically to DNase administration in the electrolytic model. The gene discussed is ADORA2A; the disease is Venous thrombosis.